{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=109", "query": { "intervention": "SC", "page": 109 }, "page_size": 10 }, "pagination": { "page": 109, "page_size": 10, "total_count": 3868, "total_pages": 387, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=110&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=108&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T11:29:53.282Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02124148", "title": "A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Metastasis", "Colorectal Neoplasms", "Breast Cancer" ], "interventions": [ { "name": "Prexasertib", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "LY3023414", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 167, "start_date": "2014-06-18", "completion_date": "2020-02-13", "has_results": false, "last_update_posted_date": "2020-04-01", "last_synced_at": "2026-11-09T11:29:53.282Z", "location_count": 5, "location_summary": "Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02124148" }, { "nct_id": "NCT05696847", "title": "A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "Tirzepatide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "6 Years to 11 Years" }, "enrollment_count": 28, "start_date": "2023-02-07", "completion_date": "2025-01-16", "has_results": true, "last_update_posted_date": "2025-08-26", "last_synced_at": "2026-11-09T11:29:53.282Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Oklahoma City, Oklahoma • Houston, Texas", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05696847" }, { "nct_id": "NCT00017004", "title": "Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia", "Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Cervical Squamous Cell Carcinoma", "Drug Toxicity", "Radiation Toxicity", "Stage IIB Cervical Cancer", "Stage III Cervical Cancer", "Stage IVA Cervical Cancer" ], "interventions": [ { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Internal Radiation Therapy", "type": "RADIATION" }, { "name": "Epoetin Alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "RADIATION", "DRUG", "BIOLOGICAL" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 114, "start_date": "2001-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-08-09", "last_synced_at": "2026-11-09T11:29:53.282Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00017004" }, { "nct_id": "NCT05185843", "title": "A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Familial Chylomicronemia Syndrome" ], "interventions": [ { "name": "Olezarsen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2022-02-25", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2025-12-12", "last_synced_at": "2026-11-09T11:29:53.282Z", "location_count": 4, "location_summary": "Huntington Beach, California • Boca Raton, Florida • Ann Arbor, Michigan + 1 more", "locations": [ { "city": "Huntington Beach", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05185843" }, { "nct_id": "NCT05412004", "title": "Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Obstructive Sleep Apnea", "Obesity" ], "interventions": [ { "name": "Tirzepatide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 469, "start_date": "2022-06-21", "completion_date": "2024-03-29", "has_results": true, "last_update_posted_date": "2025-04-30", "last_synced_at": "2026-11-09T11:29:53.282Z", "location_count": 18, "location_summary": "Riverside, California • Brandon, Florida • Ocala, Florida + 15 more", "locations": [ { "city": "Riverside", "state": "California" }, { "city": "Brandon", "state": "Florida" }, { "city": "Ocala", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05412004" }, { "nct_id": "NCT02614261", "title": "Evaluation of Galcanezumab in the Prevention of Chronic Migraine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Migraine" ], "interventions": [ { "name": "Galcanezumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1117, "start_date": "2015-11-30", "completion_date": "2021-07-14", "has_results": true, "last_update_posted_date": "2022-05-18", "last_synced_at": "2026-11-09T11:29:53.282Z", "location_count": 52, "location_summary": "Phoenix, Arizona • Encino, California • Fullerton, California + 47 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Encino", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02614261" }, { "nct_id": "NCT04166773", "title": "A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nonalcoholic Steatohepatitis" ], "interventions": [ { "name": "Tirzepatide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 190, "start_date": "2019-11-19", "completion_date": "2024-01-10", "has_results": true, "last_update_posted_date": "2025-01-24", "last_synced_at": "2026-11-09T11:29:53.282Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Fresno, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Huntington Park", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04166773" }, { "nct_id": "NCT02097173", "title": "Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "medac GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 35, "start_date": "2013-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-03-17", "last_synced_at": "2026-11-09T11:29:53.282Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02097173" }, { "nct_id": "NCT04973111", "title": "A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes" ], "interventions": [ { "name": "CT-868 as SC Injection", "type": "DRUG" }, { "name": "Placebo as SC Injection", "type": "DRUG" }, { "name": "Active Comparator as SC Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Carmot Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 32, "start_date": "2021-07-16", "completion_date": "2022-04-22", "has_results": false, "last_update_posted_date": "2025-03-28", "last_synced_at": "2026-11-09T11:29:53.282Z", "location_count": 1, "location_summary": "Chula Vista, California", "locations": [ { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04973111" }, { "nct_id": "NCT04488419", "title": "ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Alzheimer Disease", "Dementia of Alzheimer Type" ], "interventions": [ { "name": "ATH-1017", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "LeonaBio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "55 Years to 85 Years" }, "enrollment_count": 554, "start_date": "2020-09-28", "completion_date": "2024-07-15", "has_results": true, "last_update_posted_date": "2025-04-04", "last_synced_at": "2026-11-09T11:29:53.282Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04488419" } ] }